<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201602063168N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-02-10</date_registration>
      <primary_sponsor>Reasearch Vice-Chancellor- Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of TheraCal-LC®  and Mineral Trioxide Aggregate in direct pulp capping of primary molars in 5-8 year old children.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of TheraCal-LC®  and Mineral Trioxide Aggregate in direct pulp capping of primary molars in 5-8 year old children. A split-mouth randomized controlled clinical Trial .</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-10-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/3212</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: For this split mouth randomized controlled clinical trial study, symmetrical bilateral second primary molar teeth in maxilla or mandible were chosen in each patient according to the inclusion criteria. In each patient one of the bilateral second primary molars was allocated to group “A” (i.e. TheraCal-LC group) and the other one to group “B” (MTA group) randomly.</study_design>
      <phase>N/A</phase>
      <hc_freetext>dental caries.</hc_freetext>
      <i_freetext>Intervention 1: Study group: The effect of TheraCal LC (Bisco Inc., Schamburg, IL, USA) in direct pulp capping of primary molars. This material was applied by using its own commercial instrument with a rounded tip in a layer with maximum thickness of 1.5 millimeters and then light-cured for 20 seconds. Intervention 2: Control group: The effect of MTA (ProRoot; Dentsply, Tulsa, OK, USA) in direct pulp capping of primary molars. This material will be handled and applied to the exposure site with an MTA carrier, gently pressed with a moist cotton pellet for better adaptation with the exposure site, and then covered with a low viscosity Glass Ionomer layer (RMGI, Fuji II, LC GC, America) with a thickness of 2 mm to ensure the proper seal.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Ali Vafai</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pediatric Dentistry department,Dentistry faculty, Tabriz University of Medical Sciences , Golgasht street, Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 41 3335 5965</telephone>
        <email>alivafaiitbzmed@gmail.com</email>
        <affiliation>Dentistry faculty, Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Leila Erfanparast</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pediatric Dentistry department, Dentistry faculty, Tabriz University of Medical Sciences, Golgasht street, tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 41 3335 5965</telephone>
        <email>leilaerfan@gmail.com</email>
        <affiliation>Dentistry faculty, Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:&#13;
5-8 years old children; Complete physical and mental health with no confounding history of systemic disease and/or use of special local or systemic drugs; No allergic reactions recorded in patient history; Having a pair of symmetric second primary molar teeth in one jaw having deep caries and vital pulp which is capable of being restored by amalgam filling; No history of spontaneous pain, pathologic mobility, draining sinus tract, redness or swelling of vestibule; Normal gingival and periodontal condition, with no sensitivity to vestibular palpation, and no pain on percussion test; No sign of radiolucency in periapical or furcation area; No widening of PDL space or loss of lamina dura continuity; No evidence of internal/external pathologic root resorption.&#13;
&#13;
Exclusion criteria:&#13;
Lack of informed consent by the child patient’s parent; No evidence of pulp exposure at the site of caries excavation in second primary molar teeth, which were conventionally restored with an amalgam filling and excluded from our study; Evidence of pulp exposure surrounded by carious dentin which is indicative of pulpal contamination; Abnormal bleeding at the site of pulp exposure (i.e. bleeding with dark color which lasts for more than 3 minutes despite application of wet cotton pellet with mild pressure).</inclusion_criteria>
      <agemin>3 years</agemin>
      <agemax>8 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K02.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Caries of dentine</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Study group: The effect of TheraCal LC (Bisco Inc., Schamburg, IL, USA) in direct pulp capping of primary molars. This material was applied by using its own commercial instrument with a rounded tip in a layer with maximum thickness of 1.5 millimeters and then light-cured for 20 seconds.</i_keyword>
      <i_keyword>Control group: The effect of MTA (ProRoot; Dentsply, Tulsa, OK, USA) in direct pulp capping of primary molars. This material will be handled and applied to the exposure site with an MTA carrier, gently pressed with a moist cotton pellet for better adaptation with the exposure site, and then covered with a low viscosity Glass Ionomer layer (RMGI, Fuji II, LC GC, America) with a thickness of 2 mm to ensure the proper seal.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Dental pulp vitality after treatment. Timepoint: 6.12 months. Method of measurement: lack of any of clinical or radiographic signs or symptoms of treatment failure.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Radiographic success. Timepoint: 6, 12 months. Method of measurement: Presence of one or more of the following radiographic signs will be considered as failure of treatment: internal and/or external root resorption, periodontal space widening, inter-radicular radiolucency, and periapical lesions.</sec_outcome>
      <sec_outcome>Clinical success. Timepoint: 6, 12 months. Method of measurement: Presence of one or more of the following clinical signs/symptoms will be considered as failure of treatment: spontaneous pain, swelling,  pathologic mobility, tenderness to pressure, and presence of sinus tract, swelling, and sensitivity to percussion.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Reasearch Vice-Chancellor- Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-12-26</approval_date>
        <contact_name>Ethics Commitee of Research Department - Tabriz University of Medical Sciences</contact_name>
        <contact_address>Research Department- Tabriz University of Medical Sciences- Golgasht street- Tabriz- Iran Tabriz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
